Ballentine Partners
MIRM icon

Ballentine Partners’s Mirum Pharmaceuticals MIRM Stock Holding History

Ballentine Partners’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$285K Hold
3,339
– – ﹤0.01% 875
2026
Q2 		$391K Buy
3,339
+15
+0.5% +$1.51K ﹤0.01% 659
2026
Q1 		$307K Hold
3,324
– – ﹤0.01% 729
2025
Q4 		$263K Sell
3,324
-256
-7% -$18.4K ﹤0.01% 787
2025
Q3 		$262K Buy
+3,580
New +$228K ﹤0.01% 787

Other funds holding MIRM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 20.64% 1-Year Est. Return

Ballentine Partners's MIRM Position: Q3 2026 in Review

Ballentine Partners held its Mirum Pharmaceuticals (MIRM) position steady in Q3 2026 at 3,339 shares worth $285K. The position accounts for ﹤0.01% of the portfolio, ranked #875.

Ballentine Partners first reported a position in MIRM in Q3 2025 and has held it in 5 quarters since. The position peaked at $391K in Q2 2026. 204 funds tracked by Wall St. Rank hold MIRM as of Q3 2026.

  • Ballentine Partners held 3,339 shares of Mirum Pharmaceuticals worth $285K as of Q3 2026.
  • Ballentine Partners left its Mirum Pharmaceuticals share count unchanged in Q3 2026.
  • Mirum Pharmaceuticals made up ﹤0.01% of Ballentine Partners's portfolio in Q3 2026, its #875 holding.
  • Ballentine Partners first reported a position in Mirum Pharmaceuticals in Q3 2025 and has held it in 5 quarters since.
  • Ballentine Partners's Mirum Pharmaceuticals position peaked at $391K in Q2 2026.
  • 204 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q3 2026.

Based on Ballentine Partners's 13F filing for Q3 2026, filed 13 Nov 2026.